MET and neoplasm: Our exploratory findings, particularly the observed enrichment of tumor responses in the RAS wild-type subgroup along with upregulation of MET signaling pathway in responders, likely explain the more favorable outcome seen in the CAMILLA and COSMIC-021 trials.